Nivolumab +/- Ipilimumab with Chemotherapy in Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1, open-label trial of nivolumab and ipilimumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of patients with dose limiting toxicities with weekly paclitaxel/carboplatin plus nivolumab at 6 weeks and Number of patients with dose limiting toxicities weekly paclitaxel/carboplatin plus nivolumab and ipilimumab at 6 weeks. Started Aug 2017; status: completed.